ABSTRACT
Background Men who have sex with men (MSM) and people who inject drugs (PWID) carry a disproportionate burden of HIV and hepatitis C virus (HCV) infections. We compared the demographic and risk profiles of MSM who inject drugs (MSM-IDU, i.e., men reached through affiliation with MSM) and PWID who are men and have sex with men (PWID-MSM, i.e., men reached through affiliation with PWID).
Methods We used data from the most recent waves of the National HIV Behavioural Surveillance among MSM (2017) and PWID (2018) in San Francisco. Participants were recruited through venue-based (MSM) and peer-referral (PWID) sampling and completed standardised questionnaires. We compared the characteristics of MSM-IDU and PWID-MSM using bivariate tests.
Results Of 504 participants completing the MSM survey, 6.2% reported past-year injection drug use (MSM-IDU). Among 311 male participants completing the PWID survey, 19.0% reported past-year sex with a male (PWID-MSM). Relative to MSM-IDU, more PWID-MSM were older, identified as bisexual, had lower income, a history of incarceration and were homeless. MSM-IDU had more male sexual partners (median: 10 vs 3) and fewer injected daily (29.0% vs 64.4%) than PWID-MSM. While more PWID-MSM sought sterile equipment from a syringe program (86.4% vs 35.5%), fewer reported using PrEP (15.0% vs 42.9%).
Conclusion The sociodemographic, risk behaviour, and prevention access profiles of MSM-IDU and PWID-MSM in San Francisco suggest that they represent distinct populations who may require tailored HIV and HCV prevention strategies. MSM- and PWID-focused prevention programs should provide combined sexual health and harm reduction messages and services.
Competing Interest Statement
PV received an unrestricted research grant from Gilead that is not related to this study. SNF acknowledges consulting support from Gilead Sciences and from End Hep C SF; neither are related to this study. All other authors have no competing interests to report.
Funding Statement
AA is supported through postdoctoral fellowships through the Canadian Institute of Health Research, Fonds de recherche du Québec - Santé and Canadian Network on Hepatitis C. PV acknowledges support from the National Institute of Health Research Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol and the National Institute for Drug Abuse (NIDA; R01DA033679, R21 DA047902). The parent study, National HIV Behavioral Surveillance (NHBS), is funded by the US Centers for Disease Control and Prevention (CDC, 5U1BPS003247). The funding sources had no role in the design and conduct of this study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRBs of the University of California, San Francisco and US Centers for Disease Control and Prevention gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Source of Funding: AA is supported through postdoctoral fellowships through the Canadian Institute of Health Research, Fonds de recherche du Québec – Santé and Canadian Network on Hepatitis C. PV acknowledges support from the National Institute of Health Research Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol and the National Institute for Drug Abuse (NIDA; R01DA033679, R21 DA047902). The parent study, National HIV Behavioral Surveillance (NHBS), is funded by the US Centers for Disease Control and Prevention (CDC, 5U1BPS003247). The funding sources had no role in the design and conduct of this study, the collection, management, analysis, and interpretation of the data, or the preparation or approval of the manuscript.
Conflicts of interest: PV received an unrestricted research grant from Gilead that is not related to this study. SNF acknowledges consulting support from Gilead Pharmaceuticals and from End Hep C SF; neither are related to this study. All other authors have no competing interests to report.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos